clinical trial · NCT06799546
A Phase III Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy
Haisco Pharmaceutical Group Co., Ltd.·phase3·completed·n = 73
PNHHSK39297 tabletsEculizumab Injection
brief summary
The purpose of this study is to evaluate the efficacy and safety of HSK39297 tablets compared to eculizumab in Patients with PNH who Are Naive to Complement Inhibitor Therapy.
started
Feb 13, 2025
primary completion
Nov 5, 2025
completion
Nov 5, 2025
last updated
Dec 22, 2025
official title
A Phase III, Multicenter, Randomized, Open Label, Active-Controlled Study to Evaluate the Efficacy and Safety of HSK39297 Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Are Naive to Complement Inhibitor Therapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol